Mesenchymal Stem Cell Compositions via Centrifugal Filtration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for purifying mesenchymal stem cells (MSCs) result in high levels of xenogeneic substances, such as bovine serum albumin (BSA) and porcine trypsin, leading to allergic reactions, immune responses, and potential transmission of diseases, while also causing MSC aggregation, which can lead to pulmonary emboli.
Innovation Solution
Purification of MSCs using centrifugal filtration to reduce xenogeneic substances, particularly BSA, and minimize aggregation by decreasing adhesive properties, resulting in compositions with reduced immunogenicity and safer therapeutic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional purification methods are used, then MSCs can be isolated and expanded, but high levels of xenogeneic substances remain leading to allergic reactions and immune responses
Solution Approach 1:
The patent applies extraction by removing xenogeneic substances (bovine serum albumin, porcine trypsin) from the MSC composition through multiple washes and centrifugation steps. The method extracts these harmful macro-molecules while retaining the therapeutic MSCs, directly resolving the contradiction between maintaining MSC functionality and eliminating immunogenic contaminants.
Solution Approach 2:
The patent discards xenogeneic substances through repeated washing and centrifugation cycles, recovering only the human MSCs. Each wash cycle removes a portion of the contaminating proteins, and the process is repeated until xenogeneic substance levels are reduced to safe thresholds, thereby recovering pure MSCs free from immunogenic contaminants.
2Ease of manufacture
If conventional purification methods are used, then MSCs can be processed, but MSC aggregation occurs leading to pulmonary emboli
Solution Approach 1:
The patent applies preliminary action by performing gentle washes and centrifugation at optimized speeds before final MSC formulation. This preliminary processing removes xenogeneic substances without causing cell damage or aggregation, preparing the MSCs for safe administration. The method establishes proper cell handling conditions early in the process to prevent aggregation later.
Solution Approach 2:
The patent changes physical parameters including centrifugation speed, wash solution composition, and incubation conditions to optimize MSC processing. By adjusting these parameters, the method achieves effective removal of xenogeneic substances while maintaining MSCs in a non-aggregated, administrable state, resolving the contradiction between processing efficiency and preventing harmful aggregation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a significant reduction in xenogeneic substances and MSC aggregation, enhancing the safety and efficacy of MSC compositions by minimizing allergic reactions and pulmonary emboli risks.
Implementation Method 1
Purification of MSCs using centrifugal filtration to reduce xenogeneic substances
Data Source
AI summary
One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed.